Trial Profile
A reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 Aug 2017
Price :
$35
*
At a glance
- Drugs Migalastat (Primary)
- Indications Fabry's disease
- Focus Expanded access; Therapeutic Use
- 07 Aug 2017 According to an Amicus Therapeutics media release, 179 patients (treatment naive and ERT switch) reimbursed Galafold as of July 31, 2017.
- 09 May 2017 According to an Amicus Therapeutics media release, 100 patients (treatment naive and ERT switch) reimbursed Galafold as of April 30, 2017
- 09 Jan 2017 According to an Amicus Therapeutics media release, 61 patients are being treated on reimbursed Galafold as of December 31, 2016. The company targets to treat 300 patients by year-end 2017.